Skip to Content
Merck
All Photos(1)

Key Documents

F7751

Sigma-Aldrich

Fluoxymesterone

solid (photosensitive)

Synonym(s):

11β,17β-Dihydroxy-9α-fluoro-17α-methyl-4-androsten-3-one, 9α-Fluoro-11β,17β-dihydroxy-17α-methylandrost-4-en-3-one, 9α-Fluoro-11β-hydroxy-17α-methyltestosterone

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H29FO3
CAS Number:
Molecular Weight:
336.44
EC Number:
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:

biological source

Porcine pancreas
bovine milk (other parts like skeletal muscle/bile/bone/connective tissue/skin)
microbial (Mycobacterium sp.)

form

solid (photosensitive)

drug control

USDEA Schedule III; Home Office Schedule 4.2; regulated under CDSA - not available from Sigma-Aldrich Canada

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

color

white

solubility

H2O: ≤0.5 mg/mL
45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 6.4 mg/mL
ethanol: 7.3 mg/mL

application(s)

forensics and toxicology
veterinary

shipped in

ambient

storage temp.

room temp

SMILES string

[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)CC[C@]34C

InChI

1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1

InChI key

YLRFCQOZQXIBAB-RBZZARIASA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Fluoxymesterone is an androgen and anabolic steroid.

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Repr. 2

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C L Loprinzi et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17(10), 3299-3306 (1999-10-03)
Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed
G W Sledge et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18(2), 262-266 (2000-01-19)
Although hormonal therapy represents standard therapy for metastatic hormone-sensitive disease, many patients receive initial chemotherapy because of the location, bulk, or aggressiveness of their disease. It is uncertain whether simultaneous hormonal therapy provides additional benefit compared with chemotherapy alone. Eastern
A A Welder et al.
Journal of pharmacological and toxicological methods, 33(4), 187-195 (1995-08-01)
Hepatic complications in athletes and bodybuilders after abusing anabolic-androgenic steroids (AAS) have been reported. Hepatic injury, including cholestasis, peliosis hepatis, hyperplasia, and tumors, have been attributed to abuse of the 17 alpha-alkylated AAS. Some of these pathological conditions have been
M Perloff et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14(5), 1589-1598 (1996-05-01)
To compare two cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP) regimens with a doxorubicin-based regimen--vinblastine, doxorubicin, thiotepa, and Halotestin (Upjohn, Kalamazoo, MI) (VATH)--in patients with stage II node-positive breast carcinoma. Nine hundred forty-five women were treated with a 6-week induction
J Aisner et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13(6), 1443-1452 (1995-06-01)
We sought to compare three doxorubicin-based therapies for metastatic breast cancer for response frequency, time to treatment failure (TTF), and survival. Women with metastatic breast cancer who had measurable disease, required laboratory tests, had received no prior chemotherapy for metastases

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service